GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2013

Neurelis, Biotie Therapies Enter Option and Merger Agreement

  • San Diego-based specialty pharmaceutical company Neurelis and Finnish specialized drug development firm Biotie Therapies have entered into an agreement to further develop the former’s NRL-1 (intranasal diazepam), and to provide the latter with the exclusive option to acquire all its outstanding shares of its merger target.

    Under the terms of the option and merger agreement between the companies, Biotie will first pay Neurelis $1 million for the exclusive option to acquire all the NRL-1-developer’s outstanding shares. Then, during the negotiated option period, Biotie will conduct the development program for NRL-1— indicated for the management of patients requiring intermittent diazepam to control bouts of acute repetitive seizure activity—and work alongside Neurelis to advance the program with the FDA in preparation for NDA submission.

    If Biotie exercises its merger option, it will pay out $8.75 million in new ordinary shares. Neurelis stockholders would also be eligible to receive additional payments based on certain regulatory and commercial milestones.

    In a statement, Neurelis president and CEO Craig C. Chambliss said: “We are excited at the prospect of working with Biotie on the continued development of NRL-1, with the goal of bringing this promising and unique therapy to patients with epilepsy. The proven success of Biotie’s development efforts and the potential of an intranasal diazepam program with unmatched bioavailability and a well-tolerated safety profile could significantly benefit patients who experience acute repetitive seizures.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »